MSD's doravirine/islatravir combo yields positive results in Phase 3 HIV-1 trials The doravirine/islatravir combination met primary efficacy and safety objectives in two Phase 3 trials involving adults with virologically suppressed HIV-1 Read more: https://lnkd.in/eXVpmm4k #pharmanews #gileadsciences #pharmaceuticalindustry #clinicaltrials #clinicalresearch #hiv #MSD #WorldPharma
